A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Commentary|Videos|June 13, 2025
Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS
Author(s)Johannes Schetelig, MD, MSc
Fact checked by: Ashling Wahner , Caroline Seymour
Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.
Advertisement
Johannes Schetelig, MD, director of medical research at DKMS; as well as a professor at Technical University Dresden, discussed findings from the phase 2/3 HAMLET trial (NCT03275636) comparing survival outcomes with haploidentical related and single human leukocyte antigen loci–mismatched unrelated donor transplantation in patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The supplemental new drug application was submitted under the accelerated approval pathway with a request for priority review.
The FDA approved ropeginterferon alfa-2b for the treatment of essential thrombocythemia.
The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
3
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
4
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
5